ArticleEye and vision (London, England)2016
Clinical outcomes of combined versus separate carbachol and brimonidine drops in correcting presbyopia.
Article in Eye and vision (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- Enhancing presbyopia treatment: A comparative study of 1% Pilocarpine monotherapy versus combination with 0.09% Bromfenac.Indian journal of ophthalmology · 2026Trial
- The Science of Pseudoaccommodation and Its Therapeutic Potential.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Current Trends in Presbyopia Correction-A Comprehensive Review.Journal of clinical medicine · 2025Review
- Pharmacological Modulation of Pupil Size in Presbyopia: Optical Modeling and Clinical Implications.Journal of clinical medicine · 2025Article
- Brimonidine tartrate 0.15% drops to reduce low post-LASIK residual myopia: A retrospective study.PloS one · 2025Article
- Correction of presbyopia using 0.5% pilocarpine eye drops among Indians.Bioinformation · 2024Article
- Pharmacological treatment of presbyopia: A systematic review.European journal of translational myology · 2022Article
- Living with presbyopia: experiences from a virtual roundtable dialogue among impacted individuals and healthcare professionals.BMC ophthalmology · 2022Article
- Pharmacological Treatment in Presbyopia.Journal of clinical medicine · 2022Review
- Presbyopia - A Review of Current Treatment Options and Emerging Therapies.Clinical ophthalmology (Auckland, N.Z.) · 2021Review
- Improvement of Presbyopia Using a Mixture of Traditional Chinese Herbal Medicines, Including Cassiae Semen, Wolfberry, andEvidence-based complementary and alternative medicine : eCAM · 2021Article
- Pharmacological Therapy for Presbyopia in Patients with Previous Corneal Refractive Surgery: A Pilot Study.Ophthalmology and therapy · 2020Article
- Latanoprost could exacerbate the progression of presbyopia.PloS one · 2019Article
- An updated systematic review of pharmacological treatments for presbyopia.Advances in ophthalmology practice and researchReview
- A Review of Pharmacological Presbyopia Treatment.Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo test and compare in a masked fashion the efficacy of using a parasympathomimetic drug (3% carbachol) and an alpha-2 agonist (0.2% brimonidine) in both combined and separate forms to create optically beneficial miosis to pharmacologically improve vision in presbyopia.
methodsA prospective, double-masked, randomized, controlled clinical trial was conducted. Ten naturally emmetropic and presbyopic subjects between 42 and 58 years old with uncorrected distance visual acuity of at least 20/20 in both eyes without additional ocular pathology were eligible for inclusion. All subjects received 3% carbachol and 0.2% brimonidine in both combined and separate forms, 3% carbachol alone and 0.2% brimonidine (control) alone in their non-dominant eye in a crossover manner with one week washout between tests. The subjects' pupil sizes and both near and distance visual acuities will be evaluated pre- and post-treatment at 1, 2, 4, and 8 h, by a masked examiner at the same room illumination.
resultsStatistically significant improvement in mean near visual acuity (NVA) was achieved in all subjects who received combined 3% carbachol and 0.2% brimonidine in the same formula compared with those who received separate forms or carbachol alone or brimonidine alone (
conclusionBased on the data, the combined solution demonstrated greater efficacy than the other solutions that were tested. Improving the depth of focus by making the pupil small caused statistically significant improvement in near visual acuity, with no change in binocular distance vision.
trial registrationACTRN12616001565437. Registered 11 November 2016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.